Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
February 28 2018 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, today announced the company’s support of
the 11th annual Rare Disease Day on February 28, 2018. Rare Disease
Day emphasizes the importance of rare disease research toward the
development of diagnostic tools, treatments and cures, as well as
improved health and social care for patients and their families.
Catalyst continues to support patient
organizations that provide disease awareness for Lambert-Eaton
Myasthenic Syndrome, Congenital Myasthenic Syndromes and anti-body
positive MuSK myasthenia gravis. These are rare diseases in which
patients are often misdiagnosed with other diseases prior to
receiving a definitive diagnosis. Therefore, educating the patient
and physicians at medical congresses is an important outreach to
the rare disease community to facilitate proper and prompt
diagnoses.
“Catalyst is proud to support Rare Disease Day
and once again be part of this global movement to raise awareness
for rare diseases,” said Patrick J. McEnany, Chairman and CEO of
Catalyst. “With the upcoming resubmission of our NDA for Firdapse®,
we are one step closer to hopefully being able to provide a
treatment for those afflicted by the rare disease Lambert-Eaton
Myasthenic Syndrome.”
Rare Disease Day takes place every year on the
last day of February (February 28 or February 29 in a leap year) to
underscore the nature of rare diseases and the challenges such
patients face on a day-to-day basis. It was established in Europe
in 2008 by EURORDIS, the organization representing rare disease
patients in Europe, and is now observed in more than 80 nations.
Rare Disease Day is sponsored in the U.S. by the National
Organization for Rare Disorders (NORD)®, the largest and leading
independent, nonprofit organization committed to the
identification, treatment, and cure of rare diseases and one which
Catalyst actively supports. Additionally, Catalyst supports
Global Genes in their efforts to continue to get more patients with
rare diseases to take an active role in raising awareness about
those diseases.
For more information about Rare Disease Day in
the U.S., go to http://www.rarediseaseday.us. For information
about global activities, go to www.rarediseaseday.org. To search
for information about rare diseases, visit NORD's website
www.rarediseases.org and Global Gene's website
https://globalgenes.org/wrdd2018/.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused
on developing and commercializing innovative therapies for people
with rare debilitating, chronic neuromuscular and neurological
diseases, including Lambert-Eaton myasthenic syndrome (LEMS),
congenital myasthenic syndromes (CMS), MuSK antibody positive
myasthenia gravis, and infantile spasms. Firdapse® has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) for the treatment of LEMS and Orphan Drug
Designation for LEMS, CMS and myasthenia gravis. Firdapse is the
first and only approved drug in Europe for symptomatic treatment in
adults with LEMS.
Catalyst is also developing CPP-115 to treat refractory
infantile spasms. CPP-115 has been granted U.S. Orphan Drug
Designation for the treatment of infantile spasms by the FDA and
has been granted E.U. Orphan Medicinal Product Designation for the
treatment of West syndrome by the European Commission. In
addition, Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements involve known and unknown risks and
uncertainties, which may cause Catalyst's actual results in future
periods to differ materially from forecasted results. A number of
factors, including (i) whether the results of the LMS-003 trial,
combined with the results of the Company's previous Phase 3 trial,
will be acceptable to the FDA as support for an approval of
Firdapse for the treatment of LEMS, (ii) whether the results of the
abuse liability studies undertaken by Catalyst will be acceptable
to the FDA as support for an approval of Firdapse, (iii) whether
any NDA submitted for Firdapse will be accepted by the FDA, and the
timing of any such submission and acceptance, (iv) whether the
receipt of breakthrough therapy designation for Firdapse will
expedite the development and review of Firdapse by the FDA or the
likelihood that the product will be found to be safe and effective,
(v) whether, if an NDA for Firdapse is accepted for filing, such
NDA will be given a priority review by the FDA, (vi) whether
Firdapse will ever be approved for commercialization, (vii) whether
Catalyst will be the first company to receive an approval for
amifampridine (3,4-DAP), giving it 5-year marketing exclusivity for
its product, and (viii) those other factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2016 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024